Episode Details

It’s July 2nd. As of yesterday Seniors who have a Part D plan (prescription drug plan) who want to lose weight can choose from three GLP-1s for $50/month for the next 18 months (as long as they meet the BMI/health condition gates which we will dive into below and aren’t excluded for specified reasons).

Yesterday I went on national news again to make sure the information provided was accurate. Bianca de la Garza - Emmy nominated and award winning TV host, anchor of Bianca Across the Nation daily on Newsmax (12-2pm ET) has a fantastic new Living Longer segment that aligns with our Food Is Health work. And we’re excited to be collaborating when helpful to bring timely and relevant insights to her audience.

I know, it is scary to jump off a cliff without a parachute when it comes to GLP-1 use aka without lifestyle (nutrition/strength and more) support. A $50 drug without a food system is not a health structure. It is a temporary discount on a downstream intervention.

But when ~50% of Seniors have a metabolic condition the saying “desperate times call for desperate measures” comes to mind. Loudly.

And the glaring Bridge program gap is what the BALANCE program is for. And I heard some reassuring news firsthand earlier this week. A few of the brilliant folks I’d want to be involved have indeed been summoned to work on the program design.

The Bridge Program

Medicare has never been allowed to cover GLP-1 drugs for weight loss. That changed yesterday by utilizing the Section 402 demonstration authority (42 U.S.C. \mathsection 1395b-1), which allows CMS to test temporary, short-term pilot programs outside of the standard Medicare Part D system.

It’s important you remember that because knowing that authority exists for System C innovation should give EVERYONE hope. It’s not about asking for handouts, it’s about creative, innovative system design.

This program does not cover Ozempic. Not Mounjaro. Not the drugs people casually name at dinner parties because the brand recognition got there before everything else did. The new Medicare GLP-1 Bridge covers a specific list of obesity medications, for eligible beneficiaries, at $50 a month, from July 1, 2026 through December 31, 2027.

Obesity is not a character flaw. It is not a failure of discipline. It is biology, food environment, stress, medication history, sleep, poverty, trauma, hormones, marketing, and a thousand other things that get flattened into a before-and-after photo.

So if a senior who has been metabolically stuck for years can finally access a medication that helps, should we shame them and/or scold them?

What if instead we build something BEFORE the Balance program is up and running that ensures they don’t end up plagued by frailty, sarcopenia, etc. And that the success they might achieve on the drug is sustained.

I am also interested in asking the question we overlook.

What happens after the appetite signal changes?

Because that is where the real story begins.

Program Details

* Eligible Medicare Part D beneficiaries can get these three specific GLP-1 weight-loss medications for a flat $50 monthly copay.

* The approved drugs are Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen only.

* The $50 DOES NOT cover the cost of obtaining the prescription.

* The program runs through the end of 2027.

* It operates outside the normal Part D coverage and payment flow, with pharmacy eligibility confirmation and Medicare approval.

* The prior authorization required from a prescriber will last the entire 18 months, but the scripts can only be filled for 30 days at a time.

* Prescribers don’t need to be Medicare eligible or accept Medicare, seniors do not need to go to their current doctor, however they